k.kuusela

TL2 · Coimbra

Contributes reviews on supplier material. Based in Coimbra.

Joined 27 September 2025 · last posted 6d

74 posts, newest first. Showing up to 150.

Prior authorisation: what the criteria usually require — a second dataset Replied, post #56 · Access › Insurance & coverage · 22 Jul 2026 · 7 likes Adding the boring version of Prior authorisation, because the interesting version keeps getting posted and the boring one is usually right. Check the ordinary…
Coming back to: Delayed gastric emptying and oral medication absorption: which drugs… Replied, post #39 · Practice › Interactions · 18 Jul 2026 · 3 likes I would call the community position on Delayed gastric emptying and oral likely rather than established, and I would be comfortable defending that hedge.
[2026 update] Detection wavelength and why 214 nm and 280 nm disagree Replied, post #47 · Analytics › HPLC & UHPLC · 18 Jul 2026 · 0 likes Coming back to post #45, because the follow-up matters more than the original answer. Trifluoroacetic acid at 0.1 per cent is the near-universal ion-pairing additive…
What I would want from a home test that does not exist yet — what changed since Replied, post #96 · Analytics › Home & field testing · 16 Jul 2026 · 15 likes Reconstitution behaviour is a legitimate home observation. A cake that will not dissolve, a solution that hazes, visible particulate — all are real information and all…
Primary endpoint hierarchies and why order matters — one year on Replied, post #43 · Evidence › Trials · 11 Jul 2026 · 0 likes Dropout is information: high dropout rates can indicate tolerability problems or lower efficacy than the summary suggests. Where the analysis handled dropouts matters.…
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction Replied, post #30 · Compounds › Retatrutide · 11 Jul 2026 · 20 likes No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial of this compound is either a misreading or an invention, and the honest…
What a certificate commits its issuer to Replied, post #12 · Analytics › COA interpretation · 11 Jul 2026 · 11 likes Peptide content and chromatographic purity are separate determinations and a certificate that reports only one has answered only one question. Content is the one that…
A site rotation scheme that is easy enough to actually follow — a second dataset Replied, post #5 · Practice › Administration · 8 Jul 2026 · 0 likes I had written a reply contradicting the opening post and deleted it. Here is what survived. Bleeding at the injection site: normal and usually minimal. A little blood…
The report format the maintainers ask for, and why each field is there Replied, post #2 · Sourcing › Vendor reports · 24 Jun 2026 · 0 likes I read the opening post twice before replying, because I had assumed the opposite. A difference inside method repeatability is not a disagreement. Saying so in your own…
Coming back to: Why a preprint's supplementary material is often the best part Replied, post #83 · Evidence › Preprints · 19 Jun 2026 · 0 likes A preprint reporting a null result is more likely to stay a preprint, which biases the published literature and makes preprint servers more valuable rather than less. I…
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #4 · Compounds › Retatrutide · 18 Jun 2026 · 1 like The opening post and I disagree about the size of the effect, not about the direction. Mass and identity: a report on retatrutide should state the mass detected by…
Does dual agonism explain the effect size, or is it dose? Replied, post #21 · Compounds › Tirzepatide · 7 Jun 2026 · 6 likes The honest answer on dual agonism is that it depends, and the useful part is the list of what it depends on. Four items, in rough order of how much they matter. Most…
Request: show the solution author in the topic list — what changed since Replied, post #34 · Meta › Feature requests · 1 May 2026 · 0 likes Counter-request, gently: please do not add anything on hover. It does not exist on a phone and half the readers here are on one. Someone should write this up properly,…
A single out-of-range value on an otherwise normal panel Replied, post #41 · Clinical › Bloodwork · 1 May 2026 · 2 likes I would put moderate confidence on the mainstream reading of single out-of-range value and no more. That is not scepticism for its own sake; it is where the sourcing…
Revisiting: Theoretical plates: useful number or ritual? Replied, post #4 · Analytics › HPLC & UHPLC · 24 Apr 2026 · 0 likes On the opening post — agreed on the reasoning, with one qualification. Detection wavelength: 214 nm detects the peptide bond and is relatively insensitive to…
List price versus negotiated price versus what you pay Replied, post #109 · Access › Pricing · 17 Apr 2026 · 26 likes The most useful thing anyone has posted about list price versus negotiated price in this category was a table of what had been measured and by whom. That is what I…
Journal club: LEADER as the historical anchor Replied, post #59 · Evidence › Journal club · 12 Apr 2026 · 0 likes The baseline characteristics table is the single most useful page for the questions that get asked here, because it tells you who the result applies to. That is the…
Why oral semaglutide needs an absorption enhancer at all — one year on Replied, post #10 · Compounds › Oral incretins · 31 Mar 2026 · 27 likes Orforglipron is a small molecule rather than a peptide, which changes almost everything about how it is made, stored and analysed. Comparing it to oral semaglutide as…
Second pass at: What "verified" means on our vendor pages, stated narrowly Replied, post #87 · Sourcing › Vendor reports · 28 Mar 2026 · 18 likes Coming back to post #85, because the follow-up matters more than the original answer. Do not adjust a reported figure. Post what the laboratory said and put your…
Search filters: what is missing Replied, post #40 · Meta › Site feedback · 27 Mar 2026 · 24 likes Right — I had this wrong and I am glad to have read it before it mattered.
[2026 update] What a purity-only report leaves out Replied, post #64 · Sourcing › Independent verification · 23 Mar 2026 · 10 likes Practical experience of purity-only, offered as one case with the conditions stated, not as a general finding. Conditions first, because they are what make it…
Common supplements people ask about, assessed one at a time — a second dataset Replied, post #73 · Practice › Interactions · 23 Mar 2026 · 12 likes Worth separating two things that post #71 runs together. The claim about Common supplements upthread is stronger than its source supports. I have read the source. The…
Grapefruit: why this class is not the class that cares Replied, post #69 · Practice › Interactions · 23 Mar 2026 · 26 likes The confident answers on grapefruit and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this category.
Foaming during reconstitution and whether it matters — the long version Replied, post #70 · Practice › Reconstitution · 21 Mar 2026 · 0 likes Post #67 answers the question as asked. The question underneath it is different. Foaming during reconstitution came up in a thread eighteen months ago and was answered…
Pre-registering a personal experiment, seriously — a second dataset Replied, post #39 · Research Methods › N-of-1 designs · 5 Mar 2026 · 0 likes Record everything that changed, not just the intervention. Personal experiments are confounded by life, and the confounders are only recoverable if they were written…
How to ask about something you suspect is a bad idea Replied, post #58 · Start Here › How to Ask · 23 Feb 2026 · 23 likes Do not apologise in the first line. It costs you the space where the question should be, and nobody here thinks a question is an imposition. The conclusion is…
Measurement error in a self-reported exposure Replied, post #8 · Evidence › Study critique · 21 Feb 2026 · 4 likes Answering the question post #6 raises rather than the one it answers. Generalisability and validity are separate axes. A trial can be internally impeccable and still…
Seven-day rolling means and why weekly readings mislead — one year on Replied, post #39 · Outcomes › Progress reports · 12 Feb 2026 · 19 likes Non-scale victories: muscle gain or maintenance, clothing fit, energy level, and capability (like climbing stairs without breathlessness) are measurements that…
AOD-9604 and the fragment hypothesis, revisited — does this still hold? Replied, post #2 · Compounds › Other compounds · 18 Dec 2025 · 13 likes The opening post is the version of this I will quote in future. One addition. One caution on AOD-9604: everything above assumes the underlying documentation is what it…
Follow-up: A supplier that answers analytical questions with restated claims Replied, post #14 · Sourcing › Red flags · 13 Dec 2025 · 0 likes A supplier changing batch nomenclature is not a warning sign, and it does make historical comparison harder until a mapping exists.
Robustness: the parameters worth deliberately varying Replied, post #52 · Analytics › Method validation · 9 Dec 2025 · 14 likes I had written a reply contradicting post #48 and deleted it. Here is what survived. I would rather this thread reach "we do not know" about robustness than reach a…
What I would record differently if I started again — the long version Replied, post #18 · Outcomes › Progress reports · 30 Nov 2025 · 21 likes Menstrual cycle: for people who menstruate, weight can shift by several pounds across the cycle due to fluid retention and other factors. Noting cycle phase when…
Angle of injection and whether 90 degrees is always right Replied, post #56 · Practice › Administration · 26 Nov 2025 · 26 likes The failure mode on angle of injection is boring rather than dramatic. It is almost always the step everyone assumes was done correctly because it is too simple to get…
Documentation that materially improves an appeal's chances Replied, post #58 · Access › Insurance & coverage · 10 Nov 2025 · 8 likes Where an exception process exists separately from an appeal, they are different routes with different criteria and using the wrong one loses time. Not a strong opinion,…
History of disordered eating and why it changes the conversation Replied, post #20 · Clinical › Special populations · 1 Nov 2025 · 6 likes Counterpoint on history of disordered eating, offered without confidence: the same observation is consistent with a much duller explanation, and nobody has ruled the…
Specification in the result column: why that is a meaningful error Replied, post #66 · Analytics › COA interpretation · 31 Oct 2025 · 29 likes An itemised related-substances table with retention times says considerably more about the synthesis than a single total. A total tells you how much is not the main…
Revisiting: German, French and Dutch differences, compared Replied, post #93 · Regional › European Union · 27 Oct 2025 · 3 likes Prescription status is harmonised at the level of the authorisation and the practical route to a prescription is not. I have left out the parts I could not verify.
The most useful thing you learned here that was not the answer you came for — a second… Replied, post #122 · Lounge › Off topic · 26 Oct 2025 · 27 likes Industry and supply chain: post about manufacturing, pharmaceutical economics, or market dynamics if you have something substantive to contribute. That much is…
A parcel that arrived warm: a decision process, not a verdict Replied, post #77 · Practice › Storage & stability · 10 Oct 2025 · 19 likes Visible particulate is a strong signal in the other direction: it is a reason to stop and ask rather than to filter and proceed.
Escalating every six weeks instead of four: what I observed over eight months — one year… Replied, post #59 · Practice › Dosing & titration · 20 Sep 2025 · 20 likes Escalating before steady state means you are judging a dose you have not yet fully experienced. That is the whole argument against compressing the schedule and it is a…
Sleep quality changes during weight loss — what changed since Started this topic · Wellbeing › Sleep · 13 Sep 2025 · 55 likes Sleep quality changes during weight loss — what changed since Writing it up because I had to work it out twice and would rather nobody else did. What changes if the…
Coming back to: Amylin analogue mechanism: satiety signalling separate from GLP-1 Replied, post #12 · Compounds › Cagrilintide & amylin analogues · 18 Jul 2025 · 0 likes Gastric emptying: both amylin and GLP-1 slow it, through partly overlapping but distinct mechanisms. Whether the slowing at a higher magnitude produces disproportionate…
Follow-up: The lowest dose that does anything: is that a real question? Replied, post #32 · Practice › Dosing & titration · 18 Jul 2025 · 12 likes Coming back to post #29, because the follow-up matters more than the original answer. Holding a dose indefinitely: the trials did not study indefinite holding at a…
A field-by-field walk through a certificate of analysis Replied, post #16 · Analytics › COA interpretation · 14 Jul 2025 · 5 likes The version of field-by-field walk through a certificate that circulates here is a simplification of a simplification. It is not wrong, but it has lost the conditions…
What this community means by "a source", in practical terms Replied, post #34 · Start Here › Welcome · 14 Jul 2025 · 0 likes Worth knowing early: the archive is not retrospectively corrected. A topic from two years ago was accurate when written and may not be now. Every post carries its date…
Reading a rodent study on a secretagogue without over-extrapolating Replied, post #23 · Compounds › Secretagogues & GH axis · 9 Jul 2025 · 0 likes Picking up post #22: that is the part I would want checked first. Growth hormone secretagogues act on the ghrelin receptor or on the growth hormone releasing hormone…
Splitting a vial for two laboratories: how to do it without ruining both Replied, post #66 · Sourcing › Independent verification · 20 Jun 2025 · 10 likes The four services answer different questions. A documentation review cannot tell you what is in a vial and a purity assay cannot tell you whether the records are…
Follow-up: Tracking intake honestly when appetite is absent Replied, post #63 · Nutrition & Training › Protein & intake · 11 Jun 2025 · 0 likes Post #61 describes the usual case. This is about the unusual one. Fibre and fluid tend to fall alongside protein when intake drops, and the constipation reported here…
Coming back to: Cross-border purchase rules within the EU Replied, post #6 · Regional › European Union · 22 May 2025 · 9 likes Prescription status is harmonised at the level of the authorisation and the practical route to a prescription is not. Happy to be corrected if someone holds better data…
Second pass at: Triple agonism: additive, synergistic, or neither? Replied, post #52 · Compounds › Retatrutide · 18 May 2025 · 23 likes Confirming post #50 from a second method, which matters more than confirming it from a second person. Triple agonism at GLP-1, GIP and glucagon receptors is the…
Follow-up: Requesting a page: what makes a good request Replied, post #23 · Documentation › Wiki requests · 18 Apr 2025 · 2 likes The strongest case for a new document is a question that recurs and has a good answer buried in a reply. That is the promotion criterion as written.
Hepatic steatosis: what the MASH trial evidence supports Replied, post #21 · Clinical › Comorbidities · 17 Apr 2025 · 20 likes Type 2 diabetes: the population with the largest evidence base for these compounds. The SURPASS and SUSTAIN programmes established glycaemic benefit. The renal and…
Retatrutide dose escalation in the published trials Replied, post #131 · Compounds › Retatrutide · 14 Apr 2025 · 23 likes Retatrutide dose escalation has a well-known answer and a correct answer, and the interesting work is establishing that they are the same. Nobody has done that here yet.
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly Replied, post #54 · Compounds › Tirzepatide · 5 Apr 2025 · 3 likes Post #50 and I disagree about the size of the effect, not about the direction. I have three months of notes on tirzepatide in type 2 diabetes and the honest summary is…
Second pass at: Retatrutide mass and identity: what a report should show Replied, post #5 · Compounds › Retatrutide · 17 Mar 2025 · 9 likes Where I part company with post #3, and it is a narrow parting. Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not…
One lot is one lot: when a report becomes a pattern — the long version Replied, post #13 · Sourcing › Vendor reports · 15 Mar 2025 · 18 likes Post #12 is the version of this I will quote in future. One addition. Reports of ordinary results are more valuable than reports of remarkable ones, precisely because…
Biased agonism: a real phenomenon, an over-used explanation Replied, post #28 · Pharmacology › Receptor biology · 2 Mar 2025 · 26 likes GIP receptor signalling: the glucose-dependent insulinotropic peptide receptor (GIP) is involved in glucose-stimulated insulin secretion. GIP agonism is thought to…
Obstructive sleep apnoea and a hard endpoint in this class Replied, post #15 · Clinical › Comorbidities · 15 Feb 2025 · 12 likes A history of pancreatitis appears in the cautions for this class and the decision around it is one that needs a clinician who knows the history. It is one reading of…
Validating a method you did not develop — does this still hold? Replied, post #6 · Analytics › Method validation · 13 Feb 2025 · 21 likes Specificity is the first question: does the method separate the analyte from everything reasonably expected to be present? A method that has not been challenged with…
How compounding permissions changed when supply normalised Replied, post #11 · Sourcing › Regulatory · 22 Jan 2025 · 1 like Post #7 describes the usual case. This is about the unusual one. Where a claim about legality is made here, the useful follow-up is which instrument it rests on. Most…
Coming back to: Preparing for an appointment: one page, three questions Replied, post #132 · Clinical › Prescriber conversations · 26 Dec 2024 · 26 likes Questions about dose: asking "how will we determine whether this dose is working for me" gets at the monitoring plan. Asking "can we start lower" or "can we escalate…
[2026 update] Journal club: SURPASS-2 and the semaglutide 1 mg comparator Replied, post #61 · Evidence › Journal club · 15 Dec 2024 · 10 likes SURPASS-2 sits at the boundary between what this community can usefully discuss and what it cannot, and I think it falls on the discussable side, narrowly.
Athletes in weight-category sports: a different risk calculus — a second dataset Replied, post #39 · Clinical › Special populations · 7 Dec 2024 · 0 likes Good question, well framed, and I would like to see it answered properly.
Meeting a protein target on a suppressed appetite — does this still hold? Replied, post #25 · Nutrition & Training › Protein & intake · 27 Nov 2024 · 3 likes The version of Meeting a protein target that I was taught turned out to be a teaching simplification. Useful, and not true in the way I had assumed it was.
Coming back to: Grapefruit: why this class is not the class that cares Replied, post #29 · Practice › Interactions · 22 Nov 2024 · 29 likes Adding the measurement that post #26 says would settle it. SGLT2 inhibitors: frequently co-administered and relevant to renal and cardiovascular discussion, not to…
SNAC and the mechanism of oral peptide absorption — the long version Replied, post #10 · Compounds › Oral incretins · 11 Nov 2024 · 1 like Picking up post #9: that is the part I would want checked first. PIONEER 6 was a cardiovascular safety trial for oral semaglutide, not an efficacy trial.…
Follow-up: Dead volume across syringe and needle combinations Replied, post #55 · Devices › Syringes & needles · 26 Oct 2024 · 29 likes Needle length for subcutaneous delivery is a question about tissue depth and injection angle together. Short needles at ninety degrees and longer ones at an angle reach…
[2026 update] Journal club: SURPASS-2 and the semaglutide 1 mg comparator Replied, post #8 · Evidence › Journal club · 13 Oct 2024 · 0 likes Post #5 is the version of this I will quote in future. One addition. My understanding of SURPASS-2 is a few years old and may have been superseded. If it has been, I…
Taste changes and food aversion, reported and discussed Replied, post #20 · Practice › Side effects · 17 Sep 2024 · 0 likes Post #17 is the version of this I will quote in future. One addition. The confident answers on taste changes and food aversion and the well-sourced answers are not the…
Signs of dehydration worth acting on Replied, post #10 · Safety › Adverse events · 29 Aug 2024 · 3 likes Post #7 is right about the mechanism and I think understates the practical bit. Acute kidney injury: rare but reported. Symptoms (decreased urine output, creatinine…
Second pass at: Retatrutide dose escalation in the published trials Replied, post #63 · Compounds › Retatrutide · 20 Jul 2024 · 13 likes No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial of this compound is either a misreading or an invention, and the honest…
Over-dilution: when your dose falls below one readable graduation Started this topic · Practice › Reconstitution · 14 Jul 2024 · 0 likes On the subject in the title: Over-dilution: when your dose falls below one readable graduation Working notes rather than a conclusion. I have read the maintained page…
Oral contraceptives and delayed emptying: what the data shows Replied, post #34 · Practice › Interactions · 12 Jul 2024 · 20 likes The practical advice most consistently given by pharmacists here is to keep the timing of other oral medication consistent rather than to change it, because consistency…
Cold packs, phase-change material, and what survives ten days Replied, post #52 · Sourcing › Logistics · 28 Jun 2024 · 33 likes Useful. I have added it to my own notes with the date on it.